JB Chemicals to file review plea in NGT against plant closure

Image
Press Trust of India New Delhi
Last Updated : Feb 09 2016 | 4:57 PM IST
JB Chemicals & Pharmaceuticals today said it will file a review petition before the National Green Tribunal (NGT) after the Supreme Court stayed the direction issued by the tribunal for closure of its bulk drugs plant in Gujarat.
The Supreme Court has also directed the drug firm to file a review petition before the green body.
In a regulatory filing, JB Chemicals & Pharmaceuticals said the Supreme Court has by order passed on January 29 stayed the order issued by the NGT for closure of company's bulk drugs plant at Panoli, Gujarat, for four weeks and directed the company to file review petition before the NGT.
"The company is now in the process of filing a review petition before the NGT," it added.
Elaborating on the order, the company said the SC order also provides that NGT will extend the period of stay on merits of contentions till disposal of the review petition.
The NGT (West Zone) via order dated January 8, 2016 termed the environmental clearance given to the plant by the Centre as "illegal" and "directed the Government of India to revoke within one month the environment clearance granted to the company's plant".
Consequently, the NGT had also directed the company to close down the activities at the said plant within four weeks.
The NGT order had come after the Paryavartan Suraksha Samiti, Vododara and Peoples Union for Civil Liberties, Ankleshwar challenged the environment clearance to the manufacturing facility.
During 2014-15, total sales of bulk drugs manufactured at the said plant amounted to Rs 104 crore. Besides, the company also uses active pharmaceutical ingredients (APIs) produced at this plant for captive consumption.
JB Chemicals & Pharmaceuticals stock was trading at Rs 254, down 3.35 per cent, on the BSE.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 09 2016 | 4:57 PM IST

Next Story